The short half-life of BPC-157 (less than 30 minutes) suggests frequent dosing might optimize tissue levels, yet the peptide initiates cellular processes that continue after clearance
Avoid repeated freeze-thaw cycles, as this can degrade peptides
Satisfied patients rarely file BBB reports
Figure 1: Cumulative Distribution of Response for Belly Appearance Distress Extension Phase (Weeks 26-52) In the double-blind Extension Phase, patients on a 2 mg dose of EGRIFTA (1 mg/vial formulation) completing the 26-week Main Phase were re-randomized to receive a 2 mg dose of EGRIFTA (1 mg/ vial formulation) or placebo
At French Peptides, all neuropeptides are sold exclusively as in vitro and preclinical research materialsthey are not intended for human consumption
These events were predominantly mild to moderate and transient, and only 5.9% of participants discontinued treatment, indicating an overall acceptable safety and tolerability profile